Jason Lettmann, ALX Oncology CEO (Lightstone Ventures)
October 3, 2023 07:34 AM EDTUpdated 11:24 AM
R&D

Up­dat­ed: In turn­around, ALX On­col­o­gy’s CD47 block­er shows ef­fi­ca­cy in gas­tric can­cer tri­al

Lei Lei Wu

News Reporter

Don’t write off CD47 just yet.

ALX On­col­o­gy said that 52% of gas­tric can­cer pa­tients who re­ceived its an­ti-CD47 drug evor­pacept in com­bi­na­tion with a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

Maze's ALS spin­out Trace Neu­ro­science rais­es $101M for ALS and neu­ro work

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

Up­dat­ed: As­traZeneca, Dai­ichi Sankyo re­place lung can­cer fil­ing for En­her­tu suc­ces­sor

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times